EA201592120A1 - Состав на основе наночастиц, содержащий антагонист trpa1 - Google Patents

Состав на основе наночастиц, содержащий антагонист trpa1

Info

Publication number
EA201592120A1
EA201592120A1 EA201592120A EA201592120A EA201592120A1 EA 201592120 A1 EA201592120 A1 EA 201592120A1 EA 201592120 A EA201592120 A EA 201592120A EA 201592120 A EA201592120 A EA 201592120A EA 201592120 A1 EA201592120 A1 EA 201592120A1
Authority
EA
Eurasian Patent Office
Prior art keywords
trpa1
composition based
antagonist
nanoparticles containing
nanoparticles
Prior art date
Application number
EA201592120A
Other languages
English (en)
Inventor
Улхас Дхуппад
Сунил Чаудхари
Суреш Раджуркар
Нелиш Джаин
Original Assignee
Гленмарк Фармасьютикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гленмарк Фармасьютикалс С.А. filed Critical Гленмарк Фармасьютикалс С.А.
Publication of EA201592120A1 publication Critical patent/EA201592120A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к составу на основе наночастиц, который содержит антагонист анкирин-1 рецептора ионного канала с транзиторным рецепторным потенциалом ("TRPA1"). Конкретно, данное изобретение относится к составу на основе наночастиц, который содержит производное тиенопиримидиндиона в качестве антагониста TRPA1 и поверхностный стабилизатор, к способу получения такого состава и к его применению при лечении респираторного нарушения или боли у субъекта.
EA201592120A 2013-06-20 2014-06-20 Состав на основе наночастиц, содержащий антагонист trpa1 EA201592120A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2090MU2013 2013-06-20
PCT/IB2014/062462 WO2014203210A1 (en) 2013-06-20 2014-06-20 Nanoparticulate formulation comprising a trpa1 antagonist

Publications (1)

Publication Number Publication Date
EA201592120A1 true EA201592120A1 (ru) 2016-04-29

Family

ID=51136536

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592120A EA201592120A1 (ru) 2013-06-20 2014-06-20 Состав на основе наночастиц, содержащий антагонист trpa1

Country Status (13)

Country Link
US (1) US10603277B2 (ru)
EP (1) EP3010489A1 (ru)
JP (1) JP2016522251A (ru)
CN (1) CN105307642A (ru)
AP (1) AP2015008919A0 (ru)
AU (1) AU2014282762B2 (ru)
BR (1) BR112015030341A2 (ru)
CA (1) CA2912578A1 (ru)
EA (1) EA201592120A1 (ru)
HK (1) HK1221161A1 (ru)
MX (1) MX2015016024A (ru)
PH (1) PH12015502820A1 (ru)
WO (1) WO2014203210A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016042501A1 (en) * 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
PL3568122T3 (pl) * 2017-01-10 2024-03-18 Dukebox Sp. Z O.O. Sposób wytwarzania zawiesiny nanocząsteczek soli potasowej albo soli magnezowej
HUE056959T2 (hu) * 2018-09-11 2022-04-28 Lead Biotherapeutics Ltd Mukoadheziv diszperziós nanorészecske rendszer és eljárás annak elõállítására

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IT1298575B1 (it) 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
US8771740B2 (en) 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US7998507B2 (en) 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
UA76810C2 (ru) 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтическая композиция антагониста рецептора тахикинина в форме наночастиц
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
EP1863450A1 (en) * 2005-03-16 2007-12-12 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
DK2411397T3 (da) 2009-03-23 2013-08-05 Glenmark Pharmaceuticals Sa Isothiazol-pyrimidindionderivater som modulatorer af TRPA1
PL2411395T3 (pl) * 2009-03-23 2013-10-31 Glenmark Pharmaceuticals Sa Pochodne furopirymidynodionu jako modulatory TRPA1
WO2010141805A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
JP2013507364A (ja) 2009-10-07 2013-03-04 メルク・シャープ・エンド・ドーム・コーポレイション 新規なｔｒｐａ１アンタゴニスト
WO2012176105A1 (en) * 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
IN2014MN02467A (ru) 2012-06-08 2015-07-10 Glenmark Pharmaceuticals Sa

Also Published As

Publication number Publication date
AU2014282762B2 (en) 2016-11-10
US20140377358A1 (en) 2014-12-25
MX2015016024A (es) 2016-04-04
JP2016522251A (ja) 2016-07-28
AU2014282762A1 (en) 2015-11-26
BR112015030341A2 (pt) 2017-07-25
AP2015008919A0 (en) 2015-12-31
WO2014203210A1 (en) 2014-12-24
CN105307642A (zh) 2016-02-03
PH12015502820A1 (en) 2016-03-21
CA2912578A1 (en) 2014-12-24
EP3010489A1 (en) 2016-04-27
HK1221161A1 (zh) 2017-05-26
US10603277B2 (en) 2020-03-31

Similar Documents

Publication Publication Date Title
MX2019005192A (es) Compuestos de quinolina selectivamente sustituida.
MX363708B (es) Compuestos de quinolina selectivamente sustituidos.
UA113440C2 (xx) Сполуки тетрагідропіразолопіримідину
CY1119042T1 (el) Υποκατεστημενες ξανθινες και μεθοδοι χρησης αυτων
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
PH12016500141A1 (en) Methods of treating sporadic inclusion body myositis
PH12015502788A1 (en) Antibody formulations and methods
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
MX2022010324A (es) Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
EA201690728A1 (ru) Применение молекул, связывающих семафорин-4d, для лечения атеросклероза
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
PH12015501627A1 (en) Kv1.3 antagonists and methods of use
BR112015018047A8 (pt) método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas
EA201592120A1 (ru) Состав на основе наночастиц, содержащий антагонист trpa1
MY174711A (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
EA201691269A1 (ru) Дерматологическая композиция на основе экстрактов водорослей и листа оливы
UA109404C2 (ru) 6-(2-r-метилселено)-2-оксо-4-фенил-3,5-дициано-1,2,3,4-тетрагидропиридины